Table 2

Cartilage volume loss (%) versus baseline

CSPlacebop Values
RegionMonthMeanSDMeanSDAge*BP†
Global6−2.873.26−4.673.390.0300.0520.011
12−3.713.14−6.124.590.0210.0360.014
Lateral compartment6−1.53.4−3.694.470.0150.0280.013
12−1.513.67−5.045.020.0040.0060.002
Medial compartment6−4.435.27−5.94.70.2370.3080.116
12−6.174.67−7.737.330.2020.2760.201
Condyles6−4.914.56−5.554.860.3090.4930.187
12−5.524.37−7.325.20.0770.1330.061
Lateral condyle6−2.544.73−4.384.940.0620.1230.072
12−1.674.66−5.556.240.0060.0100.005
Medial condyle6−7.497.71−6.847.070.9710.8470.673
12−9.597.7−9.347.840.7310.9060.719
Tibial plateaus60.023.59−2.964.120.0020.0020.001
12−1.093.02−4.225.120.0170.0220.011
Lateral tibial plateau6−0.053.59−2.366.20.0180.0170.007
12−1.24.49−4.546.190.0680.0900.040
Medial tibial plateau60.556.06−3.926.220.0160.0160.009
12−0.445.12−4.848.710.0520.0590.047
Trochlea6−1.134.35−1.785.870.4860.6870.389
12−1.716.22−4.036.240.1290.1750.068
  • Data are shown for the percentage change in cartilage volume.

  • p Values of the corresponding subregions were assessed by analysis of covariance (ANCOVA) where the dependent variable was the cartilage volume at 6 and 12 months, and the independent variables were the cartilage volume at baseline and the treatment. Additional adjustment was made for *age and concomitant treatment with †bisphosphonates.

  • n=32/30 for CS, n=28/22 for placebo at 6 and 12 months, respectively.

  • BP, bisphosphonate treatment (n=4 and 1 for CS and placebo, respectively); CS, chondroitin sulphate.